Background
==========

A large amount of associations among biomedical entities are scattered in biomedical literature. Systematic analysis of such heterogeneous data provides biomedical scientists with unprecedented opportunities to infer novel associations among different biological entities in the context of personalized medicine and translational research studies. MEDLINE (<http://www.nlm.nih.gov/bsd/pmresources.html>), for instance, currently contains more than 22 million citations of biomedical literature. Semantic MEDLINE is a knowledge base consisting of associations automatically extracted from MEDLINE by integrating document retrieval, advanced natural language processing (NLP), and automatic summarization and visualization \[[@B1]\]. However, it is computationally challenging to perform queries directly from Semantic MEDLINE where associations among different biomedical entities are very complex yet sparse. It is also very difficult to investigate those associations at a large scale. Advance informatics approaches have the potential to fill gaps between knowledge needs of translational researchers and existing knowledge discovery services.

In Semantic MEDLINE, biomedical entities and associations are semantically annotated using concepts in the Unified Medical Language System (UMLS) \[[@B2]\]. The semantic information defined in the UMLS can be further leveraged to extract associations among concepts in specific domains and identify domain patterns for specific studies through advanced computational methods such as network-based analysis.

In the last decade, network-based computational approaches have gained popularity and become a new paradigm to investigate associations among drugs, diseases, and genes. Applications of these approaches include disease gene prioritization \[[@B3]-[@B5]\], identification of disease relationships \[[@B6],[@B7]\] and drug repositioning \[[@B8],[@B9]\]. However, majority of these approaches focus on relationships between only two kinds of entities (e.g., association between gene and disease). For instance, Hu and Agarwar \[[@B10]\] created a human disease-drug network based on genomic expression profiles collected from the Gene Expression Omnibus (GEO) (<http://www.ncbi.nlm.nih.gov/geo/>). In total, 170,027 interactions between diseases and drugs were considered significant, including 645 disease-disease, 5,008 disease-drug, and 164,374 drug-drug associations. These expression-based associations among diseases and drugs could serve as a backend knowledge base to facilitate discovery. Bauer-Mehren et al. \[[@B11]\] developed a comprehensive disease-gene association network by integrating associations from several sources that cover different biomedical aspects of diseases. The results indicate a highly shared genetic origin of human diseases. Functional modules were also detected in several Mendelian disorders as well as in common diseases. To systematically analyze drug-disease-gene relationships, Daminelli et al. \[[@B12]\] proposed a network-based approach to predict novel drug-gene and drug-disease associations by completing incomplete bi-cliques in the network. This approach holds great potential for drug repositioning and discovery of novel associations. However, the analysis was limited to only certain associations among drugs, genes, and diseases (e.g., drug-disease and drug-gene associations). A network-based investigation of all pair-wise associations among these entities is necessary to understand the complexity of existing associations and to infer novel associations within the context of the whole knowledgebase.

Network-based computational approaches enable us to analyze heterogeneous networks such as drug-disease-gene networks by decomposing them into small subnetworks, called network motifs (NMs) \[[@B13]\]. NMs are statistically significant recurring structural patterns found more often in real networks than would be expected in random networks with the same network topologies. They are the smallest basic functional and evolutionarily conserved units in biological networks. Our hypothesis is that NMs of a network are the significant sub-patterns that represent the backbone of the network, which serves as the focused portion out of thousands of nodes (e.g., drugs, diseases, and genes,) \[[@B14],[@B15]\]. These NMs could also form large aggregated modules that perform specific functions by forming associations in overlapping NMs.

In this paper, we propose a network-based computational framework to analyze the complex network formed by a large amount of associations. We focus on a heterogeneous drug-disease-gene network derived from Semantic MEDLINE and investigated underlying associations using network-based systems biology approaches. Three case studies demonstrate that our approach has potential to facilitate formulization of novel research hypotheses, which is critical for translational medicine research. In the following, we first present Materials and methods. We then describe the results and case studies in detail.

Materials and methods
=====================

To comprehensively investigate the integrated drug-disease-gene network formed by associations available in Semantic MEDLINE, we propose the following two-step computational framework: (1) extraction and optimization of drug-disease-gene network in Semantic MEDLINE; (2) network topology analysis of this heterogeneous network at two levels: statistics and degree distribution of high-confidence association networks, and distinct pattern detection at NM level. In this section, we first describe the steps to extract association network data from MEDLINE database, followed by a description of the proposed network-based approach to investigate this heterogeneous drug-disease-gene association network. Figure [1](#F1){ref-type="fig"} illustrates the steps of the proposed approach.

![Overview of the network-based computational framework for an integrated drug-disease-gene network.](2041-1480-5-33-1){#F1}

Data sources and preprocessing
------------------------------

### Extraction of association data from Semantic MEDLINE

Semantic MEDLINE currently contains more than 56 million associations extracted from MEDLINE citations and consists of eight tables, including concepts, concept semantic types, concept translations, predication, predication arguments, and sentences. Data from different tables need to be joined in order to obtain information for a particular association between two entities. The database contains an all-embracing joined table that provides information about associations (source concept, predicate, and object concept), and their source PubMed IDs (PMIDs).

We optimize and reorganize the relevant data in Semantic MEDLINE into the Resource Description Framework (RDF) format. Based on the UMLS semantic types and groups \[[@B16]\], we extract unique associations among drugs, diseases, and genes, and represent them in six views in relational database tables. We then use the Web RDF transformation tool D2R server to convert the six views into RDF triples through a D2RQ mapping file (<http://d2rq.org/d2r-server>). This mapping file specifies the mappings between those six relational database table schemas and the output RDF graphs \[[@B17]\]. A detailed description of this approach is described in our previous work \[[@B18]\]. These six tables are used as preliminary association data resources including all unique associations from Semantic MEDLINE.

### Data preprocessing using FDA-approved drugs in DrugBank

Since the extraction accuracy of associations in Semantic MEDLINE is about 77% (precision is 76% to 96%, and recall is 55-70%) \[[@B19]\], a filtering strategy is applied to extract high-confidence association data using the FDA-approved drug list from DrugBank, a database containing drug information and the corresponding drug target and treatment indication information \[[@B20]\]. As of July 31 2012, the database contains 1,578 FDA-approved drug entries, including 131 FDA-approved biotech drugs, and 1,447 FDA-approved small molecule drugs. We extract associations involving these FDA-approved drugs from each drug-related association table. After manually removing generic and nonsensical terms in the association tables (e.g., gene, homologous gene, and protein), we limit the drug-drug, drug-gene, and drug-disease associations to those involved in the 1,578 FDA-approved drugs. Based on the filtered drug-gene and drug-disease associations, we generate related gene and disease lists and then obtained gene-gene, disease-disease, and gene-disease associations using these genes and diseases. This filtering strategy enables us to focus on associations related to FDA-approved drugs only in this study. These associations are then analyzed by the proposed network-based approach.

Network motif analysis
----------------------

Network motifs are topologically distinct subnetwork patterns that are present more frequently in true networks than in random networks \[[@B21]\]. They are usually well conserved and possess specific processing tasks in same types of networks. For example, in gene regulatory networks, the same set of network motifs have been repeatly identified in diverse organisms from bacteria to human \[[@B22]\]. The hypothesis is that network motifs were independently selected by evolutionary processes in a converging manner and have characteristic dynamical functions \[[@B23]\]. This suggests that network motifs serve as building blocks of in gene regulatory networks that are beneficial to the organism.

In this study, we extend network motif analysis to the disease-drug-gene network. Six different types of associations among drugs, diseases, and genes are integrated into a heterogeneous disease-drug-gene network. In this network, nodes represent biomedical entities stored in the RDF triples (i.e., diseases, drugs, or genes in "subject" and "object"), and edges represent associations between two biomedical entities (i.e., relationships in "predicate"). For simplicity, we consider all associations as undirectional association relationships in this study, discarding the directionality and types in the original RDF graph. In other words, as long as there is an association between two nodes, we consider there is an edge between these two nodes. We hypothesize that even within such simplified disease-drug-gene association network, network motifs in the network can (1) represent basic inter-relationships among diseases, drugs, and genes; (2) reflect a framework in which particular functions are achieved efficiently. Specifically, we focus on three-node network motifs in this disease-drug-gene network since they are the building blocks for larger size network motifs (number of nodes \> 3) \[[@B24]\]. All connected subnetworks containing three nodes in the association network are collated into isomorphic patterns \[[@B25]\], and the frequency of the patterns are counted. We also generated 1000 random networks from the original network by switching edges between vertices and preserving the number of edges between types of nodes (i.e., disease, drug and gene). By the default of FANOMD algorithm, if the number of occurrences for each pattern is at least five in the real network, which is significantly higher than randomized networks, the pattern is considered to be a network motif. Statistical significance test is performed by computing the fraction of randomized networks in which the pattern appears at least as often as in the interaction network \[[@B24]\]. The *z* score is calculated using the following equation:

$$\mathit{Z} = \frac{\mathit{N}_{\mathit{real}} - \left\langle \mathit{N}_{\mathit{rand}} \right\rangle}{\mathit{\sigma}_{\mathit{rand}}}$$

where *N*~*real*~ is the number of times one three-node subnetwork is detected in the real network, *N*~*rand*~ is the mean number of times this subnetwork is detected in 1000 randomized networks, and σ~*rand*~ is the standard deviation of the number of times this subnetwork is detected in randomized networks. The *p* value of a motif is the number of random networks in which it occurs more often than in the original networks, divided by the total number of random networks. A pattern with *p* ≤ 0.05 is considered statistically significant. This network motif discovery procedure is performed using the FANMOD tool \[[@B26]\].

Construction of the core drug-disease-gene network
--------------------------------------------------

It has been shown that in gene regulatory networks, for each network motif, the majority of matches overlap and aggregate into homologous motif clusters \[[@B27]\]. Many of these motif clusters largely overlap with modules of known biological processes \[[@B28]\]. The clusters of overlapping matches of these motifs aggregate into a superstructure that presents the backbone of the network and is assumed to play a central role in defining the global topological organization. Accordingly, we aggregate matches of significant network motifs into a core drug-disease-gene network. In this core network, we investigate the distribution of the connectivity degree of different types of nodes. Nodes with significantly larger number of links in the network are called hub nodes, which is critical in the information flow exchange throughout the entire network.

Results
=======

An integrated drug-disease-gene network reconstructed from Semantic MEDLINE
---------------------------------------------------------------------------

We constructed a drug-disease-gene network with the following two steps:

First, we extracted unique association data from Semantic MEDLINE. Using a use-case driven database optimization approach developed in our previous work \[[@B18]\], we extracted six different types of associations from Semantic MEDLINE database. Table [1](#T1){ref-type="table"} shows basic statistics of these six groups of associations. As illustrated in Table [1](#T1){ref-type="table"}, the number of unique associations (the Unique Association column) for each type of associations is significantly less than the number of total associations (the Record column). Since the prediction accuracy of Semantic MEDLINE is approximately 77% \[[@B29]\], we used a filtering strategy to focus on associations involving FDA-approved drugs for downstream network-based analysis.

###### 

Statistics of the six extracted association types

   **Association type**   **Record in Semantic MEDLINE**   **Unique associations**   **Associations involving FDA-approved drugs**   **Unique entity number**
  ---------------------- -------------------------------- ------------------------- ----------------------------------------------- --------------------------
     Disease-Disease                2,516,049                      843,221                               1684                                 2,248
       Disease-Gene                  206,155                       111,117                              21,444                                5,954
       Disease-Drug                 3,021,256                     1,277,879                             54,996                                3,414
        Drug-Gene                    398,572                       248,491                               3758                                 1,451
        Drug-Drug                   4,780,394                     1,900,576                               266                                  382
        Gene-Gene                    108,035                       49,593                                2169                                 2,792
          Total                     11,030,461                    4,430,877                             84,317                               7,243^1^

^1^This is the unique number of entities by summarizing all the associations.

Second, we constructed association related data involving FDA-approved drugs. We applied the filtering strategy discribed in the Materials and methods section to extract association data involving FDA-approved drugs from the unique association data set. As shown in the "Associations Involving FDA-approved Drugs" column in Table [1](#T1){ref-type="table"}, the association number of each table was further reduced. We used this focused association data to construct an integrated disease-drug-gene network for downstream network-based analysis.

Network topology analysis of the core drug-disease-gene network
---------------------------------------------------------------

The network motif analysis was performed on the integrated disease-drug-gene network obtained in Section An integrated drug-disease-gene network reconstructed from Semantic MEDLINE. Since the network contains thousands of associations among 865 drugs, 2791 genes, and 3578 diseases (Table [1](#T1){ref-type="table"}), it is too complex for a direct visualization. We overcame this problem by identifying enriched network motifs and interpreting them through an enhanced visualization. Out of this heterogeneous network consisting of 84,317 associations among 7,234 entities (including drugs, diseases, and genes), five significant network motifs were identified. Figure [2](#F2){ref-type="fig"} presents detailed statistics on these network motifs. The matches of these network motifs were extracted and number of matches for each network motif was counted ("Number of Matches" column in Figure [2](#F2){ref-type="fig"}).

![Degree distribution of three biomedical entities: drug, gene, and disease.](2041-1480-5-33-2){#F2}

Based on the network motifs identified in the analysis, we constructed a core disease-drug-gene network aggregated from significant network motif instances. We then investigated the degree distribution of different types of entities in the integrated network. Figure [3](#F3){ref-type="fig"} represents the degree distribution of disease, drug, and gene nodes in the core drug-disease-gene network. All three distributions follow the power-law distribution, indicating that networks related to different types of nodes are scale-free. The majority of the nodes in the network have only a few (less than 10) links but few other nodes have a large number of links. Such distributions have been observed in many studies of biological networks \[[@B30]\]. Our analysis demonstrates for the first time that in an integrated network consisting of heterogeneous associations, the scale-free network structure still holds. The hub nodes (i..e, the nodes have a large number of links) can provide scientists future research directions.

![**Subnetworks extracted from NM 1.(A)** Overview of the subnetwork, consisting of 126 diseases and 79 genes. **(B)** Subnetwork associated with "Malignant neoplasm of prostate" and "tumor growth". **(C)** Subnetwork associated with "communicable diseases", "West Nile viral infection" and "multicentric Castleman\'s disease".](2041-1480-5-33-3){#F3}

Local network structure: from network to network motif
------------------------------------------------------

The five significant network motif patterns in Figure [2](#F2){ref-type="fig"} have strong biological meanings and could suggest scientists future directions in their research field. We provided three case studies in the following sections to illustrate results based on three significant network motifs.

### Case study 1 - prioritization of disease genes

We first investigated whether the network motif analysis could help prioritize disease genes based on the associations between diseases and their surrounding genes. One example is Network Motif 1 (NM 1) in Figure [2](#F2){ref-type="fig"}, in which two diseases that are associated with each other are also associated with one common disease gene. This indicates that diseases identified to be associated in literature are more likely to share same associated disease genes. To further investigate the relationships highlighted by NM 1, We extracted all associations relationships among 126 diseases and 79 genes in NM 1. In total, there are 71 disease-disease, 853 disease-gene, and 3 gene-gene associations (Figure [4](#F4){ref-type="fig"}(A)) in this subnetwork, suggesting that diseases that are associated with each other are more likely to associate with a group of common disease genes. For instance in Figure [4](#F4){ref-type="fig"}(B), "Malignant neoplasm of prostate" shares all 35 associated genes with "tumor growth". Similar findings have also been discovered in other studies demonstrating same functional modules/pathways being affected in similar diseases \[[@B6],[@B31],[@B32]\]. There are 10 genes only associated to "tumor growth" in literature. Such information will help scientists generate testable hypotheses of possible roles of these genes in prostate cancer research. Another example is shown in Figure [4](#F4){ref-type="fig"}(C), where "communicable diseases" was identified to have common associated genes with both "West Nile viral infection" and "multicentric Castleman's disease". Thirteen genes associated only with "communicable diseases" can be considered as candidate disease genes for the other two diseases and help scientists design future exploratory experiments. The detailed network information is presented in Additional file [1](#S1){ref-type="supplementary-material"}: File S1.

![**Subnetworks extracted from NM 4.(A)** Overview of the subnetwork, consisting of 2,664 diseases and 1,122 genes. **(B)** Subnetwork associated with "Kidney Failure" and "skin disorder".](2041-1480-5-33-4){#F4}

### Case study 2 - inference of disease relationships

Very interestingly, we also identified another similar disease-gene network motif in our analysis (NM 4). The only difference between NM 1 and NM 4 is that NM 4 doesn't have the associations between two diseases themselves. We extracted all associations among 2,664 diseases and 1,122 genes in NM 4. In total, there are 860 disease-disease, 17,242 disease-gene, and 310 gene-gene associations in this subnetwork (Figure [5](#F5){ref-type="fig"}(A)). Based on the "guilt by association" rule -- diseases similar to each other are more likely to be affected by the same genes/pathways, two diseases involved in the same NM 4 are more likely to be similar/associated than other diseases \[[@B6]\]. For instance in Figure [5](#F5){ref-type="fig"}(B), "Kidney Failure" and "skin disorder" are associated with a group of five common associated genes. A wide variety of different skin disorders have been observed in patients with kidney diseases \[[@B33]\]. One example is the "psoriasis" disease. During the treatment of psoriasis with fumaric acid derivatives, patients could develop acute kidney failure \[[@B34]\]. In the subnetwork that consists of first neighbors of these two diseases, psoriasis is also included and has common associated genes with both "kidney failure" and "skin disorder". Some genes in the network are associated with one of these diseases only but not both. To investigate enriched biological functions/processes, we performed functional enrichment analysis on neighbor genes of three diseases with Ingenuity Pathway Analysis (IPA) Suite (<http://www.ingenuity.com/>). These genes are enriched in kidney-related disease categories (Table [2](#T2){ref-type="table"}). Although a major portion of neighbor genes are related to "skin disorder" or "psoriasis" only, they have been annotated with kidney related dysfunctions in the IPA database. Given the fact that associations among thousands of diseases are complex yet incomplete, the inferred association relationships based on our network motif-based analysis can mine the significant network topology properties of association networks and guide scientists to investigate significant association relationships in future experiments. The detailed network information is presented in Additional file [2](#S2){ref-type="supplementary-material"}: File S2.

![**Subnetworks extracted from NM 2.(A)** Overview of the subnetwork, consisting of 468 disease and 162 drugs.**(B)** Subnetwork associated with "Alzheimer's Disease" and "nervous systems disorder". **(C)** Subnetwork associated with "Dobutamine" and "Doxorubicin".](2041-1480-5-33-5){#F5}

###### 

Enriched disease and disorder categories in IPA analysis

  **Category**                           **p-value**   **Molecules**
  -------------------------------------- ------------- -------------------------------------------------------------------------
  Renal Inflammation                     6.62E-09      VEGFA,COL4A5,CD40LG,APCS,IL1RN,CLU,MYH9,COL4A4,VDR,ACTN4,NFKB1,TNF,FAS
  Renal Nephritis                        6.62E-09      VEGFA,COL4A5,CD40LG,APCS,IL1RN,CLU,MYH9,COL4A4,VDR,ACTN4,NFKB1,TNF,FAS
  Congenital Heart Anomaly               3.41E-06      VEGFA,HSPG2,TRIM21,EDNRA,ECE1
  Liver Cirrhosis                        4.13E-06      ADAM17,CD40LG,C5AR1,EDNRB,BSG,PTAFR,TNF,CCR7
  Glomerular Injury                      5.22E-06      VEGFA,CLU,MYH9,ACTN4
  Cardiac Infarction                     6.38E-06      PON1,BCL2L1,CD40LG,IL1RN,HSPA1A/HSPA1B,CLU,TNNI3,TNF,LRP1
  Renal Atrophy                          7.66E-06      CD40LG,EDNRB,FGF23,EDNRA,VDR,AQP2
  Liver Damage                           9.94E-06      BCL2L1,NLRP3,BSG,IL1RN,NFKB1,TNF,FAS
  Liver Proliferation                    1.75E-05      VEGFA,SOCS3,EDNRB,IL1RN,EDNRA,NFKB1,TNF,FAS
  Pulmonary Hypertension                 3.13E-05      EDNRB,IL1RN,KIT,EDNRA
  Liver Hepatitis                        4.73E-05      BCL2L1,IL23A,TNF,CCR7,FAS
  Liver Necrosis/Cell Death              6.57E-05      SOCS3,BCL2L1,CD40LG,IL1RN,HSPD1,NFKB1,TNF,FAS
  Cardiac Inflammation                   6.64E-05      IL33,CLU,TNNI3,IL23A,NFKB1,TNF
  Heart Failure                          6.76E-05      BCL2L1,CA2,TNNI3,VDR,NFKB1,TNF,AQP2,PRKCA
  Hepatocellular Carcinoma               6.87E-05      VEGFA,CA2,BCL2L1,SOCS3,ADAM17,BSG,KEAP1,CLU,IGFBP3,S100A4,KIT,MKI67,TNF
  Liver Hyperplasia/Hyperproliferation   6.87E-05      VEGFA,CA2,BCL2L1,SOCS3,ADAM17,BSG,KEAP1,CLU,IGFBP3,S100A4,KIT,MKI67,TNF
  Renal Dysfunction                      2.46E-04      BSG,FGF23,TNF
  Cardiac Necrosis/Cell Death            3.17E-04      VEGFA,SOCS3,BCL2L1,S100B,HSPD1,TNF,LRP1,NAD+
  Cardiac Hypertrophy                    5.67E-04      IL33,ADAM17,S100A6,HSPA1A/HSPA1B,FGF23,EDNRA,DMD,VDR,NFKB1,TNF,PRKCA
  Renal Necrosis/Cell Death              5.83E-04      BCL2L1,HSPA1A/HSPA1B,IGFBP3,CLU,PAX2,NFKB1,TNF,FAS,PRKCA
  Liver Inflammation                     8.62E-04      IL1RN,FOXP3,NFKB1,TNF,FAS
  Kidney Failure                         1.37E-03      VEGFA,SLC9A3,PKD2,MYH9,VDR,TNF,AQP2
  Cardiac Proliferation                  1.66E-03      ADAM17,KIT,TNF,PRKCA
  Renal Dilation                         1.67E-03      EDNRB,EDNRA,AQP2
  Nephrosis                              2.35E-03      CLU,ACTN4
  Liver Fibrosis                         2.48E-03      VEGFA,SOCS3,EDNRB,PKD2,EDNRA,NFKB1,TNF,CCR7
  Renal Proliferation                    2.48E-03      SOCS3,HSPG2,TJP1,HSPD1,TNF,CCR7
  Increased Levels of AST                3.13E-03      TNF,FAS
  Cardiac Fibrosis                       4.69E-03      TNNI3,DMD,VDR,NFKB1,TNF,DIO3
  Increased Levels of Albumin            5.63E-03      VEGFA
  Liver Regeneration                     5.85E-03      SOCS3,IL1RN,TNF

### Case study 3 -- Drug repositioning

Network Motif 2 (NM 2) suggests another association pattern between diseases and drugs, in which two diseases associated with each other are targets for the same drug. It has been shown by Suthram et al. \[[@B7]\] that diseases with significant correlations based on mRNA gene expression data also share common drugs. This NM supports the hypothesis that similar diseases can be treated by same drugs, allowing us to make hypotheses for drugs repositioning purpose. We extracted all associations among 468 disease and 162 drugs in NM 2. In total, there are 279 disease-disease, 8,730 disease-drug, and 14 drug-drug associations in this subnetwork (Figure [6](#F6){ref-type="fig"}(A)). We further investigated whether any drugs or diseases were "hub" nodes in this subnetwork. In Figure [6](#F6){ref-type="fig"}(B), "Alzheimer's Disease" and "nervous systems disorder" are hub diseases surrounded by 51 FDA-approved drugs. Both diseases are associated with 20 common drugs, while "nervous systems disorder" has associations with additional 31 drugs. These drugs can be considered repositioned for treatment of "Alzheimer's Disease" since it is a central nervous system disorder characterized by the presence of neurofibrillary tangles, neuritic plaques and dystrophic neurites in the brain \[[@B35]\]. In Figure [6](#F6){ref-type="fig"}(C), we observed two "hub" drugs surrounding by 129 diseases, 16 of which have associations with both drugs. Dobutamine is a sympathomimetic drug used in the treatment of heart failure and cardiogenic shock. Doxorubicin is a drug used in cancer chemotherapy. Chemotherapy side effects may increase the risk of heart disease in cancer patients \[[@B36]\]. This series of underlying connections can provide clinicians potential side effects related to certain drug treatment. This could take years to study in the clinic to identify such side effects. The results derived from our approach can serve as *in silico* exploratory analysis to guide such studies. The detialed network information is presented in Additional file [3](#S3){ref-type="supplementary-material"}: File S3.

![**Statistics of significant network motifs.** Node color: black -- drug, green -- disease, red -- gene. Edge color denotes the associations between different biomedical entities: black -- association between disease and disease, yellow - association between disease and gene, green - association between disease and drug, red - association between gene and gene.](2041-1480-5-33-6){#F6}

Three-gene network motif (NM 3) was also identified in this heterogeneous network. This NM is a very common motif pattern in the protein-protein interaction network or gene regulatory network \[[@B37],[@B38]\], indicating that NM detection analysis of heterogeneous networks can identify significant NMs even enriched in a single type of associations in a heterogeneous association network.

Comparisons of network motifs from different networks
-----------------------------------------------------

Since all five network motifs identified involve only two out of three node types, we further investigated whether the networks involving only two node types can generate the same NMs. To accomplish that, we performed NM analysis on disease-gene, disease-drug and gene networks respectively. Not all NMs detected in the complete network can be detected in disease-gene, disease-drug and gene networks respectively (Additional file [4](#S4){ref-type="supplementary-material"}: File S4). The results indicate that although the NMs don't contain all three different node types due to small NM size, the additional associations still introduce additional information in the NM detection analysis.

Discussion
==========

Literature mining approaches have been successful to extract associations among biological entities in the last decade. However, such information is usually large, complex and multidimentional, making it impossible for biomedical researchers to directly investigate such data. To leverage the gap between knowledge needs of translational researchers and existing knowledge discovery services, we have proposed a network-based informatics approach to investigate the underlying relationships among different biological entities based on associations automatically extracted from literature. The proposed approach has advantages in several aspects.

Our approach is one of the first attempts to investigate the disease-drug-gene associations in an integrative manner. To demonstrate the superiority of NM analysis on the heterogeneous network, we performed NM analysis on disease-gene, disease-drug and gene networks respectively and compared results with the ones derived from the complete disease-drug-gene network. Not all network motifs detected in the complete network can be detected in disease-gene, disease-drug and gene networks respectively. The results indicates that although NMs doesn't contain all three different node types due to their small size in this study, the additional associations still introduce additional information in the analysis. In addition, NM analysis of such heterogeneous networks can extract and highlight the hotspots in the network, leading experts in different fields to generate testable hypotheses in their future research.We are aware that there are many other network analysis approaches for both social networks and biological networks. These approaches are designed for different purposes. For instance, biological networks can be interrogated by their overall properties (e.g., average clustering coefficient and overall distributions of node degrees), significant NMs, or clustered subnetworks/modules. In this work, we focus on identifying statistically significant three-node NM patterns that can help infer novel disease-drug-gene relationships. The NM analysis can decompose the whole heterogeneous network into smallest network patterns that recurrently discovered in the network, considered as the backbone associations of diseases, drugs, and genes. For instance, in NM 1 instances in Figure [2](#F2){ref-type="fig"}, most of these NMs contain the first two same diseases, while the third gene is different. By extracting all the associations involving these two diseases from the original association network, we found that while these two diseases share a significant number of associated genes, they also have some unique associations with other genes respectively. Based on the assumption that similar diseases are more likely to associate with same group (s) of genes or involve same biological processes, the genes associated only with one disease can be prioritized as candidate disease genes of the second disease. Such inference could only be possible through NM level analysis by considering significant network patterns (i.e., NMs) as well as their neighborhood in the whole network. In addition, since these NMs are statistically significant subnetworks, they represent the "real" signal from the network which usually contains considerable amount of false positive associations, especially those from literature mining techniques. Due to the limitation of computational resource, we didn't include the NMs with more than three nodes. We plan to extend our work to NMs with more nodes (i.e., \>3) when the computational resource become available. We believe that the proposed network-based approach can complement other existing network analysis methods and provide researchers a unique way to look at these huge heterogeneous networks.

From our preliminary study \[[@B18]\], we found that Semantic MEDLINE lacks of gene-gene associations since such information usually are illustrated in the main text of literature. Semantic MEDLINE contains gene-gene interaction data from PubMed literature abstracts (Figure [2](#F2){ref-type="fig"}). We included all the associations in Figure [2](#F2){ref-type="fig"} in our analysis. However, the number of gene-gene association in Semantic MEDLINE (2,169 high-confidence pairs) is relevantly small comparing to other public databases (e.g., HPRD \[[@B4]\]). For instance, we compared the gene-gene associations in Semantic MEDLINE with those in HPRD, a manually curated gene-gene association database in human \[[@B4]\]. The overlap between these two databases is very small (about 10% associations of Semantic MEDLINE can be found in HPRD). HPRD contains many more associations than Semantic MEDLINE (41,327 versus 2,169). Therefore, we believe that combining Semantic MEDLINE with other public resources (such as HPRD \[[@B39]\] and STRING \[[@B40]\]) will increase the coverage of associations and build a more comprehensive association database. Using linked data approach, it will be relatively easier to link our data graph with such databases.

Conclusions and future work
===========================

In this paper, we proposed a network-based computational framework to investigate integrated heterogeneous network extracted from MEDLINE literature, including associations among three major entity categories: drug, gene, and disease. Five significant NMs were identified and considered as the backbone of the entire network. The potential biological meanings of each network motif were further investigated. The results demonstrated that the proposed approach holds the potential to 1) prioritize candidate disease genes, 2) identify potential disease relationships, and 3) propose novel drug targets, within the context of the entire knowledge. We believe that such analyses can facilitate the process of inferring novel relationships between drugs, genes, and diseases. One future direction is to develop module-based approaches to understand associations between different biomedical entities. Modules are condensed subnetworks in a network. Modules identified in heterogeneous networks are a group of related diseases, drugs and genes, which gives researchers a focused network view of the association relationships among these entities. Topology analysis of heterogeneous networks using graphic theory can also be applied in future studies, which can lead to the identification of diseases/drugs/genes in the context of association networks. Pathway level information could also be integrated in future analyses to extend current association network.
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